Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
runimotamab + trastuzumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Runimotamab + trastuzumab** is a combination therapy under investigation for the treatment of cancers expressing human epidermal growth factor receptor 2 (**HER2**), particularly **HER2-positive breast cancer** and **HER2-expressing gastroesophageal junction (GEJ) cancers**. Runimotamab is a bispecific monoclonal antibody that targets both HER2 and CD3, thereby engaging T cells to attack HER2-expressing tumor cells, while trastuzumab is a recombinant humanized monoclonal antibody that binds and inhibits HER2. The combination is believed to synergistically enhance anti-tumor activity by leveraging both T cell engagement and well-established HER2 blockade mechanisms. Early phase clinical trials suggest improved tolerability and potential efficacy for this combination in patients with advanced or refractory HER2-positive malignancies[1][3][4][7].
- Other names
- runimotamab + trastuzumab
02
Targets
CD3 (T-cell surface glycoprotein CD3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on runimotamab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on runimotamab + trastuzumab.